November 27, 2012JAMA
Association of Warfarin Therapy Duration After Bioprosthetic Aortic Valve Replacement With Risk of Mortality, Thromboembolic Complications, and Bleeding
Why the study?
Does discontinuation of warfarin treatment within 6 months after bioprosthetic AVR surgery increase the risk of cardiovascular death?
Population
Patients after bioprosthetic aortic valve replacement (AVR) surgery
Comparison
Warfarin therapy discontinuation within 6 months vs Continuation of warfarin therapy beyond 6 months
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Warrants caution with early warfarin discontinuation after bioprosthetic AVR; leaves open need for randomized confirmation.
Structured PICO
Does discontinuation of warfarin treatment within 6 months after bioprosthetic AVR surgery increase the risk of cardiovascular death?
P
Population
Patients after bioprosthetic aortic valve replacement (AVR) surgery
I
Intervention
Warfarin therapy discontinuation within 6 months
C
Comparator
Continuation of warfarin therapy beyond 6 months
O
Outcome
Cardiovascular deathhard clinical
Discontinuing warfarin within 6 months of bioprosthetic AVR is associated with an increased risk of cardiovascular death.
Cite This Study
Mérie et al. (2012) studied this question.